abstract: PURPOSE: A phase 2 study was completed by the Korean Gynecologic Oncologic Group to evaluate the efficacy and @entity1 of concurrent chemoradiation with weekly @entity3 in @entity0 with high-risk @entity2 . METHODS AND MATERIALS: Pathologic requirements included @entity2 stages III and IV. Radiation therapy consisted of a total dose of 4500 to 5040 cGy in 5 fractions per week for 6 weeks. @entity3 60 mg/m(2) was administered once weekly for 5 weeks during radiation therapy. RESULTS: Fifty-seven @entity0 were enrolled between January 2006 and March 2008. The median follow-up time was 60.0 months (95% confidence interval [CI], 51.0-58.2). All grade 3/4 @entity1 were hematologic and usually self-limited. There was no life-threatening @entity1 . The cumulative incidence of intrapelvic recurrence sites was 1.9% (1/52), and the cumulative incidence of extrapelvic recurrence sites was 34.6% (18/52). The estimated 5-year disease-free and overall survival rates were 63.5% (95% CI, 50.4-76.5) and 82.7% (95% CI, 72.4-92.9), respectively. CONCLUSIONS: Concurrent chemoradiation with weekly @entity3 is well tolerated and seems to be effective for high-risk endometrioid @entity2 . This approach appears reasonable to be tested for efficacy in a prospective, randomized controlled study.

title: A phase 2 trial of radiation therapy with concurrent XXXX chemotherapy after surgery in @entity0 with high-risk @entity2 : a Korean Gynecologic Oncologic Group study.

answer: @entity3


abstract: PURPOSE: A phase 2 study was completed by the Korean Gynecologic Oncologic Group to evaluate the efficacy and @entity1 of concurrent chemoradiation with weekly @entity3 in @entity0 with high-risk @entity2 . METHODS AND MATERIALS: Pathologic requirements included @entity2 stages III and IV. Radiation therapy consisted of a total dose of 4500 to 5040 cGy in 5 fractions per week for 6 weeks. @entity3 60 mg/m(2) was administered once weekly for 5 weeks during radiation therapy. RESULTS: Fifty-seven @entity0 were enrolled between January 2006 and March 2008. The median follow-up time was 60.0 months (95% confidence interval [CI], 51.0-58.2). All grade 3/4 @entity1 were hematologic and usually self-limited. There was no life-threatening @entity1 . The cumulative incidence of intrapelvic recurrence sites was 1.9% (1/52), and the cumulative incidence of extrapelvic recurrence sites was 34.6% (18/52). The estimated 5-year disease-free and overall survival rates were 63.5% (95% CI, 50.4-76.5) and 82.7% (95% CI, 72.4-92.9), respectively. CONCLUSIONS: Concurrent chemoradiation with weekly @entity3 is well tolerated and seems to be effective for high-risk endometrioid @entity2 . This approach appears reasonable to be tested for efficacy in a prospective, randomized controlled study.

title: A phase 2 trial of radiation therapy with concurrent @entity3 chemotherapy after surgery in @entity0 with high-risk XXXX : a Korean Gynecologic Oncologic Group study.

answer: @entity2


abstract: PURPOSE: A phase 2 study was completed by the Korean Gynecologic Oncologic Group to evaluate the efficacy and @entity1 of concurrent chemoradiation with weekly @entity3 in @entity0 with high-risk @entity2 . METHODS AND MATERIALS: Pathologic requirements included @entity2 stages III and IV. Radiation therapy consisted of a total dose of 4500 to 5040 cGy in 5 fractions per week for 6 weeks. @entity3 60 mg/m(2) was administered once weekly for 5 weeks during radiation therapy. RESULTS: Fifty-seven @entity0 were enrolled between January 2006 and March 2008. The median follow-up time was 60.0 months (95% confidence interval [CI], 51.0-58.2). All grade 3/4 @entity1 were hematologic and usually self-limited. There was no life-threatening @entity1 . The cumulative incidence of intrapelvic recurrence sites was 1.9% (1/52), and the cumulative incidence of extrapelvic recurrence sites was 34.6% (18/52). The estimated 5-year disease-free and overall survival rates were 63.5% (95% CI, 50.4-76.5) and 82.7% (95% CI, 72.4-92.9), respectively. CONCLUSIONS: Concurrent chemoradiation with weekly @entity3 is well tolerated and seems to be effective for high-risk endometrioid @entity2 . This approach appears reasonable to be tested for efficacy in a prospective, randomized controlled study.

title: A phase 2 trial of radiation therapy with concurrent @entity3 chemotherapy after surgery in XXXX with high-risk @entity2 : a Korean Gynecologic Oncologic Group study.

answer: @entity0


abstract: BACKGROUND: At diagnosis, identification of reliable biological indicators of prognosis to allow stratification of @entity0 according to different risks is an important but still unresolved aspect in the treatment of @entity6 ( @entity6 ) @entity0 . This study aimed to explore the role of @entity9 expression on prognosis of @entity6 @entity0 . @entity0 AND METHODS: Specimens from 109 @entity0 with non-metastatic @entity6 treated at the Rizzoli Institute with neoadjuvant chemotherapy (protocols ISG/SSGIII, @entity11 , EW-2, EW-REN2, EW-REN3, EW-PILOT) and 17 @entity1 were studied. Sixty-eight @entity0 (62%) remained disease-free and 41 (38%) relapsed (median follow-up: 67 months, range 9-241 months). Expression of @entity9 and of some of its targets ( @entity8 , @entity4 , @entity7 and @entity10 ) was evaluated by qRT-PCR using TaqMan MicroRNA Assays and/or by immunohistochemistry on tissue microarrays from the same @entity0 . RESULTS: High expression of @entity9 in localized @entity2 was significantly related to better event-free and overall survival (P = 0.004). Relevance of @entity9 was confirmed by using different calibrators (normal mesenchymal stem cells and different normal tissues). By multivariate Cox regression analysis, low @entity9 expression as well as nontotal @entity3 and high levels of @entity5 dehydrogenase were all confirmed as independent risk factors associated with poor outcome. Expression of @entity9 was lower in @entity1 than in primary @entity2 . It inversely correlated with expression of @entity8 and Ki-67. CONCLUSIONS: By demonstrating its relationship with clinical outcome, we propose evaluation of @entity9 at diagnosis of @entity6 @entity0 to allow early risk stratification. Validation of these results would nonetheless ultimately need a prospective assessment.

title: Prognostic significance of @entity9 in XXXX is associated with @entity8 expression.

answer: @entity6


abstract: BACKGROUND: At diagnosis, identification of reliable biological indicators of prognosis to allow stratification of @entity0 according to different risks is an important but still unresolved aspect in the treatment of @entity6 ( @entity6 ) @entity0 . This study aimed to explore the role of @entity9 expression on prognosis of @entity6 @entity0 . @entity0 AND METHODS: Specimens from 109 @entity0 with non-metastatic @entity6 treated at the Rizzoli Institute with neoadjuvant chemotherapy (protocols ISG/SSGIII, @entity11 , EW-2, EW-REN2, EW-REN3, EW-PILOT) and 17 @entity1 were studied. Sixty-eight @entity0 (62%) remained disease-free and 41 (38%) relapsed (median follow-up: 67 months, range 9-241 months). Expression of @entity9 and of some of its targets ( @entity8 , @entity4 , @entity7 and @entity10 ) was evaluated by qRT-PCR using TaqMan MicroRNA Assays and/or by immunohistochemistry on tissue microarrays from the same @entity0 . RESULTS: High expression of @entity9 in localized @entity2 was significantly related to better event-free and overall survival (P = 0.004). Relevance of @entity9 was confirmed by using different calibrators (normal mesenchymal stem cells and different normal tissues). By multivariate Cox regression analysis, low @entity9 expression as well as nontotal @entity3 and high levels of @entity5 dehydrogenase were all confirmed as independent risk factors associated with poor outcome. Expression of @entity9 was lower in @entity1 than in primary @entity2 . It inversely correlated with expression of @entity8 and Ki-67. CONCLUSIONS: By demonstrating its relationship with clinical outcome, we propose evaluation of @entity9 at diagnosis of @entity6 @entity0 to allow early risk stratification. Validation of these results would nonetheless ultimately need a prospective assessment.

title: Prognostic significance of XXXX in @entity6 is associated with @entity8 expression.

answer: @entity9


abstract: BACKGROUND: At diagnosis, identification of reliable biological indicators of prognosis to allow stratification of @entity0 according to different risks is an important but still unresolved aspect in the treatment of @entity6 ( @entity6 ) @entity0 . This study aimed to explore the role of @entity9 expression on prognosis of @entity6 @entity0 . @entity0 AND METHODS: Specimens from 109 @entity0 with non-metastatic @entity6 treated at the Rizzoli Institute with neoadjuvant chemotherapy (protocols ISG/SSGIII, @entity11 , EW-2, EW-REN2, EW-REN3, EW-PILOT) and 17 @entity1 were studied. Sixty-eight @entity0 (62%) remained disease-free and 41 (38%) relapsed (median follow-up: 67 months, range 9-241 months). Expression of @entity9 and of some of its targets ( @entity8 , @entity4 , @entity7 and @entity10 ) was evaluated by qRT-PCR using TaqMan MicroRNA Assays and/or by immunohistochemistry on tissue microarrays from the same @entity0 . RESULTS: High expression of @entity9 in localized @entity2 was significantly related to better event-free and overall survival (P = 0.004). Relevance of @entity9 was confirmed by using different calibrators (normal mesenchymal stem cells and different normal tissues). By multivariate Cox regression analysis, low @entity9 expression as well as nontotal @entity3 and high levels of @entity5 dehydrogenase were all confirmed as independent risk factors associated with poor outcome. Expression of @entity9 was lower in @entity1 than in primary @entity2 . It inversely correlated with expression of @entity8 and Ki-67. CONCLUSIONS: By demonstrating its relationship with clinical outcome, we propose evaluation of @entity9 at diagnosis of @entity6 @entity0 to allow early risk stratification. Validation of these results would nonetheless ultimately need a prospective assessment.

title: Prognostic significance of @entity9 in @entity6 is associated with XXXX expression.

answer: @entity8


abstract: OBJECTIVE: To determine whether recent newspaper coverage of the four most common @entity3 types relates to their relative burden and national awareness months, and to identify the subject focus during high-coverage periods. DESIGN: Content analysis using the Nexis newspaper article database. SETTING: UK 2011-2012. OUTCOME MEASURES: Annual number and ranking, monthly proportions and subject of articles on @entity0 . RESULTS: 9178 articles were identified during 2011 and 2012 featuring breast (4237), prostate (1757), lung (1746) and bowel (1438) @entity3 . Peaks in monthly proportions above the 99% upper confidence limit were identified for each. @entity0 had the highest coverage of 12% and 17% during its awareness month. Smaller peaks (11%) were identified during Bowel Cancer @entity5 . @entity4 received high coverage in relation to the case of the @entity1 convicted of the Lockerbie bombing who had been diagnosed with the @entity3 in relation to the deaths of celebrities. @entity0 was covered most often overall and by newspaper category while the lower coverage of other @entity3 types did not consistently mirror the relative number of new cases each year. The peaks by newspaper category were similar to the overall coverage with few exceptions. CONCLUSIONS: UK newspaper coverage of common @entity3 types other than of the breast appears under-represented relative to their population burden. Coverage of @entity0 appears to be influenced by their awareness months, while that of @entity4 and @entity2 is influenced by other media stories. Health-promoting public bodies and campaigners could learn from the success of @entity0 Awareness Month and work more closely with journalists to ensure that the relevant messages reach wider audiences.

title: Coverage of common XXXX types in UK national newspapers: a content analysis.

answer: @entity3


abstract: OBJECTIVES: To examine the association between trial sponsorship and conflicts of interest ( @entity2 ) with clinical trial conclusions for @entity1 trials related to radiotherapy. MATERIALS AND METHODS: The MEDLINE database was searched for all @entity1 clinical trials published between 2004 and 2013 and identified 1396 studies. Two investigators independently identified trials published in the English language of >= 30 @entity0 , and extracted relevant data. Clinical trials were classified according to trial characteristics, sponsorship source and type, @entity2 , and study conclusion, and analyzed by univariable and multivariable logistic regression. RESULTS: Of 240 eligible trials, 160 (67.5%) evaluated drugs without radiotherapy, 60 (25%) involved radiotherapy, and 18 (7.5%) involved procedures without radiotherapy. Of the 60 radiotherapy trials eligible for analysis, positive sponsorship and potential @entity2 were present in 58.3% and 20% of trials, respectively. Study conclusions were positive, negative, or neutral in 78.3%, 5%, and 16.7% of trials, respectively. No association was found between positive conclusions and either industry support of potential @entity2 . Positive conclusions were reported in 86.7% and 83.3% of trials with sponsorship and @entity2 , respectively, as compared with 75.6% and 77.1% of those without sponsorship (P=0.37) and @entity2 (P=0.64). Sponsorship was significantly associated with radiotherapy trials combined with drugs (odds ratio 5.5, P=0.01) and higher-risk disease (odds ratio 4.71, P=0.01). CONCLUSIONS: The presence of sponsorship was associated with radiotherapy trials involving drugs or studying @entity1 . However, there were no identified associations between study conclusion and sponsorship type or @entity2 .

title: Self-reported Conflicts of Interest and Trial Sponsorship of Clinical Trials in XXXX Involving Radiotherapy.

answer: @entity1


abstract: BACKGROUND: Whether the mutant allele frequency (MAF) may also have predictive implications for @entity3 kinase inhibitor (TKI) therapy in @entity0 with advanced @entity2 ( @entity2 )-mutated @entity4 (AELAd) remains unknown. @entity0 AND METHODS: Based on a biobanking system in conjunction with our institution, we assessed @entity2 mutation status using pyrosequencing (Py) and by outsourcing laboratory tests, such as the Cycleave (Cy) and the Scorpion ARMS (A). RESULTS: Out of 705 @entity0 enrolled in the Shizuoka @entity1 Mutation Study between July 2011 and March 2013, 102 AELAd @entity0 were identified as carrying the @entity5 mutation (L858Rm) using Py to analyze histological specimens. Of these 102 @entity0 , the @entity2 mutation status was assessed using both Py and Cy in 48 @entity0 : the median MAF of @entity5 (MAFLR) was 18.5% (range: 8%-82%), and 45 @entity0 (94%) were identified as having an L858Rm using both Py and Cy. Three @entity0 (6%) with discrepant L858Rm findings were only identified using Py. The plotting of a receiver operating characteristic curve to identify the discordance in L858Rm findings showed that the area under the curve for MAFLR was 0.967 (95% confidence interval: 0.91-1) and that an MAFLR of 9% resulted in high sensitivity (100%) and specificity (99%). Also, 29 @entity0 with AELAd, excluding those with postoperative recurrences, had their @entity5 status assessed using Cy or A. The median age, 69 years (range: 47-84 years); male/female, 14 (48%)/15 (52%); smokers/never-smokers 13 (45%)/16 (55%); ECOG PS 0-1/2-3, 26 (90%)/3 (10%); stage IIIB/IV, 4 (14%)/25 (86%); median MAFLR, 18% (range: 8%-63%). @entity0 with an MAFLR of  <=9% had a significantly shorter progression-free survival (PFS) period after TKI therapy than those with an MAFLR of >9% (mPFS: 92 versus 284 days, P = 0.0027). CONCLUSION: The MAF may be a potential predictive factor of TKI treatment efficacy in @entity0 with AELAd carrying the L858Rm.

title: Mutant allele frequency predicts the efficacy of @entity2 -TKIs in XXXX harboring the @entity5 mutation.

answer: @entity4


abstract: BACKGROUND: Whether the mutant allele frequency (MAF) may also have predictive implications for @entity3 kinase inhibitor (TKI) therapy in @entity0 with advanced @entity2 ( @entity2 )-mutated @entity4 (AELAd) remains unknown. @entity0 AND METHODS: Based on a biobanking system in conjunction with our institution, we assessed @entity2 mutation status using pyrosequencing (Py) and by outsourcing laboratory tests, such as the Cycleave (Cy) and the Scorpion ARMS (A). RESULTS: Out of 705 @entity0 enrolled in the Shizuoka @entity1 Mutation Study between July 2011 and March 2013, 102 AELAd @entity0 were identified as carrying the @entity5 mutation (L858Rm) using Py to analyze histological specimens. Of these 102 @entity0 , the @entity2 mutation status was assessed using both Py and Cy in 48 @entity0 : the median MAF of @entity5 (MAFLR) was 18.5% (range: 8%-82%), and 45 @entity0 (94%) were identified as having an L858Rm using both Py and Cy. Three @entity0 (6%) with discrepant L858Rm findings were only identified using Py. The plotting of a receiver operating characteristic curve to identify the discordance in L858Rm findings showed that the area under the curve for MAFLR was 0.967 (95% confidence interval: 0.91-1) and that an MAFLR of 9% resulted in high sensitivity (100%) and specificity (99%). Also, 29 @entity0 with AELAd, excluding those with postoperative recurrences, had their @entity5 status assessed using Cy or A. The median age, 69 years (range: 47-84 years); male/female, 14 (48%)/15 (52%); smokers/never-smokers 13 (45%)/16 (55%); ECOG PS 0-1/2-3, 26 (90%)/3 (10%); stage IIIB/IV, 4 (14%)/25 (86%); median MAFLR, 18% (range: 8%-63%). @entity0 with an MAFLR of  <=9% had a significantly shorter progression-free survival (PFS) period after TKI therapy than those with an MAFLR of >9% (mPFS: 92 versus 284 days, P = 0.0027). CONCLUSION: The MAF may be a potential predictive factor of TKI treatment efficacy in @entity0 with AELAd carrying the L858Rm.

title: Mutant allele frequency predicts the efficacy of @entity2 -TKIs in @entity4 harboring the XXXX mutation.

answer: @entity5


abstract: BACKGROUND: Whether the mutant allele frequency (MAF) may also have predictive implications for @entity3 kinase inhibitor (TKI) therapy in @entity0 with advanced @entity2 ( @entity2 )-mutated @entity4 (AELAd) remains unknown. @entity0 AND METHODS: Based on a biobanking system in conjunction with our institution, we assessed @entity2 mutation status using pyrosequencing (Py) and by outsourcing laboratory tests, such as the Cycleave (Cy) and the Scorpion ARMS (A). RESULTS: Out of 705 @entity0 enrolled in the Shizuoka @entity1 Mutation Study between July 2011 and March 2013, 102 AELAd @entity0 were identified as carrying the @entity5 mutation (L858Rm) using Py to analyze histological specimens. Of these 102 @entity0 , the @entity2 mutation status was assessed using both Py and Cy in 48 @entity0 : the median MAF of @entity5 (MAFLR) was 18.5% (range: 8%-82%), and 45 @entity0 (94%) were identified as having an L858Rm using both Py and Cy. Three @entity0 (6%) with discrepant L858Rm findings were only identified using Py. The plotting of a receiver operating characteristic curve to identify the discordance in L858Rm findings showed that the area under the curve for MAFLR was 0.967 (95% confidence interval: 0.91-1) and that an MAFLR of 9% resulted in high sensitivity (100%) and specificity (99%). Also, 29 @entity0 with AELAd, excluding those with postoperative recurrences, had their @entity5 status assessed using Cy or A. The median age, 69 years (range: 47-84 years); male/female, 14 (48%)/15 (52%); smokers/never-smokers 13 (45%)/16 (55%); ECOG PS 0-1/2-3, 26 (90%)/3 (10%); stage IIIB/IV, 4 (14%)/25 (86%); median MAFLR, 18% (range: 8%-63%). @entity0 with an MAFLR of  <=9% had a significantly shorter progression-free survival (PFS) period after TKI therapy than those with an MAFLR of >9% (mPFS: 92 versus 284 days, P = 0.0027). CONCLUSION: The MAF may be a potential predictive factor of TKI treatment efficacy in @entity0 with AELAd carrying the L858Rm.

title: Mutant allele frequency predicts the efficacy of XXXX -TKIs in @entity4 harboring the @entity5 mutation.

answer: @entity2


abstract: BACKGROUND: E2303 evaluated cetuximab, @entity6 , and @entity7 used as induction therapy and concomitant with radiation therapy in @entity0 with stage III/IV @entity4 ( @entity4 ) determining pathologic complete response (CR), event-free survival (EFS), and @entity2 . @entity0 AND METHODS: @entity0 with resectable stage III/IV @entity4 underwent induction therapy with planned primary site restaging biopsies (at week 8 in clinical complete responders and at week 14 if disease persisted). Chemoradiation (CRT) began week 9. If week 14 biopsy was negative, @entity0 completed CRT (68-72 Gy); otherwise, resection was carried out. @entity5 protein expression status was correlated with response/survival. RESULTS: Seventy-four @entity0 were enrolled; 63 were eligible. Forty-four (70%) were free of surgery to the primary site, progression, and death 1-year post-treatment. Following induction, 41 (23 CR) underwent week 8 primary site biopsy and 24 (59%) had no @entity1 (pathologic CR). Week 14 biopsy during chemoradiation (50 Gy) in 34 (15 previously positive biopsy; 19 no prior biopsy) was negative in 33. Thus 90% of eligible @entity0 completed CRT. Overall survival and EFS were 78% and 55% at 3 years, respectively. Disease progression in 23 @entity0 (37%) was local only in 10 (16%), regional in 5 (8%), local and regional in 2 (3%), and distant in 5 @entity0 (8%). There were no treatment-related @entity3 . @entity2 was primarily hematologic or radiation-related. @entity5 AQUA score was not associated with response/survival. CONCLUSIONS: Induction cetuximab, @entity6 , and @entity7 followed by the same drug CRT is safe and induces high primary site response and promising survival. CLINICAL TRIALS NUMBER: NCT 00089297.

title: Induction cetuximab, @entity6 , and XXXX followed by chemoradiation with cetuximab, @entity6 , and @entity7 for @entity1 : a phase II ECOG-ACRIN trial (E2303).

answer: @entity7


abstract: BACKGROUND: E2303 evaluated cetuximab, @entity6 , and @entity7 used as induction therapy and concomitant with radiation therapy in @entity0 with stage III/IV @entity4 ( @entity4 ) determining pathologic complete response (CR), event-free survival (EFS), and @entity2 . @entity0 AND METHODS: @entity0 with resectable stage III/IV @entity4 underwent induction therapy with planned primary site restaging biopsies (at week 8 in clinical complete responders and at week 14 if disease persisted). Chemoradiation (CRT) began week 9. If week 14 biopsy was negative, @entity0 completed CRT (68-72 Gy); otherwise, resection was carried out. @entity5 protein expression status was correlated with response/survival. RESULTS: Seventy-four @entity0 were enrolled; 63 were eligible. Forty-four (70%) were free of surgery to the primary site, progression, and death 1-year post-treatment. Following induction, 41 (23 CR) underwent week 8 primary site biopsy and 24 (59%) had no @entity1 (pathologic CR). Week 14 biopsy during chemoradiation (50 Gy) in 34 (15 previously positive biopsy; 19 no prior biopsy) was negative in 33. Thus 90% of eligible @entity0 completed CRT. Overall survival and EFS were 78% and 55% at 3 years, respectively. Disease progression in 23 @entity0 (37%) was local only in 10 (16%), regional in 5 (8%), local and regional in 2 (3%), and distant in 5 @entity0 (8%). There were no treatment-related @entity3 . @entity2 was primarily hematologic or radiation-related. @entity5 AQUA score was not associated with response/survival. CONCLUSIONS: Induction cetuximab, @entity6 , and @entity7 followed by the same drug CRT is safe and induces high primary site response and promising survival. CLINICAL TRIALS NUMBER: NCT 00089297.

title: Induction cetuximab, @entity6 , and @entity7 followed by chemoradiation with cetuximab, @entity6 , and XXXX for @entity1 : a phase II ECOG-ACRIN trial (E2303).

answer: @entity7


abstract: BACKGROUND: E2303 evaluated cetuximab, @entity6 , and @entity7 used as induction therapy and concomitant with radiation therapy in @entity0 with stage III/IV @entity4 ( @entity4 ) determining pathologic complete response (CR), event-free survival (EFS), and @entity2 . @entity0 AND METHODS: @entity0 with resectable stage III/IV @entity4 underwent induction therapy with planned primary site restaging biopsies (at week 8 in clinical complete responders and at week 14 if disease persisted). Chemoradiation (CRT) began week 9. If week 14 biopsy was negative, @entity0 completed CRT (68-72 Gy); otherwise, resection was carried out. @entity5 protein expression status was correlated with response/survival. RESULTS: Seventy-four @entity0 were enrolled; 63 were eligible. Forty-four (70%) were free of surgery to the primary site, progression, and death 1-year post-treatment. Following induction, 41 (23 CR) underwent week 8 primary site biopsy and 24 (59%) had no @entity1 (pathologic CR). Week 14 biopsy during chemoradiation (50 Gy) in 34 (15 previously positive biopsy; 19 no prior biopsy) was negative in 33. Thus 90% of eligible @entity0 completed CRT. Overall survival and EFS were 78% and 55% at 3 years, respectively. Disease progression in 23 @entity0 (37%) was local only in 10 (16%), regional in 5 (8%), local and regional in 2 (3%), and distant in 5 @entity0 (8%). There were no treatment-related @entity3 . @entity2 was primarily hematologic or radiation-related. @entity5 AQUA score was not associated with response/survival. CONCLUSIONS: Induction cetuximab, @entity6 , and @entity7 followed by the same drug CRT is safe and induces high primary site response and promising survival. CLINICAL TRIALS NUMBER: NCT 00089297.

title: Induction cetuximab, @entity6 , and @entity7 followed by chemoradiation with cetuximab, @entity6 , and @entity7 for XXXX : a phase II ECOG-ACRIN trial (E2303).

answer: @entity1


abstract: BACKGROUND: E2303 evaluated cetuximab, @entity6 , and @entity7 used as induction therapy and concomitant with radiation therapy in @entity0 with stage III/IV @entity4 ( @entity4 ) determining pathologic complete response (CR), event-free survival (EFS), and @entity2 . @entity0 AND METHODS: @entity0 with resectable stage III/IV @entity4 underwent induction therapy with planned primary site restaging biopsies (at week 8 in clinical complete responders and at week 14 if disease persisted). Chemoradiation (CRT) began week 9. If week 14 biopsy was negative, @entity0 completed CRT (68-72 Gy); otherwise, resection was carried out. @entity5 protein expression status was correlated with response/survival. RESULTS: Seventy-four @entity0 were enrolled; 63 were eligible. Forty-four (70%) were free of surgery to the primary site, progression, and death 1-year post-treatment. Following induction, 41 (23 CR) underwent week 8 primary site biopsy and 24 (59%) had no @entity1 (pathologic CR). Week 14 biopsy during chemoradiation (50 Gy) in 34 (15 previously positive biopsy; 19 no prior biopsy) was negative in 33. Thus 90% of eligible @entity0 completed CRT. Overall survival and EFS were 78% and 55% at 3 years, respectively. Disease progression in 23 @entity0 (37%) was local only in 10 (16%), regional in 5 (8%), local and regional in 2 (3%), and distant in 5 @entity0 (8%). There were no treatment-related @entity3 . @entity2 was primarily hematologic or radiation-related. @entity5 AQUA score was not associated with response/survival. CONCLUSIONS: Induction cetuximab, @entity6 , and @entity7 followed by the same drug CRT is safe and induces high primary site response and promising survival. CLINICAL TRIALS NUMBER: NCT 00089297.

title: Induction cetuximab, XXXX , and @entity7 followed by chemoradiation with cetuximab, @entity6 , and @entity7 for @entity1 : a phase II ECOG-ACRIN trial (E2303).

answer: @entity6


abstract: BACKGROUND: E2303 evaluated cetuximab, @entity6 , and @entity7 used as induction therapy and concomitant with radiation therapy in @entity0 with stage III/IV @entity4 ( @entity4 ) determining pathologic complete response (CR), event-free survival (EFS), and @entity2 . @entity0 AND METHODS: @entity0 with resectable stage III/IV @entity4 underwent induction therapy with planned primary site restaging biopsies (at week 8 in clinical complete responders and at week 14 if disease persisted). Chemoradiation (CRT) began week 9. If week 14 biopsy was negative, @entity0 completed CRT (68-72 Gy); otherwise, resection was carried out. @entity5 protein expression status was correlated with response/survival. RESULTS: Seventy-four @entity0 were enrolled; 63 were eligible. Forty-four (70%) were free of surgery to the primary site, progression, and death 1-year post-treatment. Following induction, 41 (23 CR) underwent week 8 primary site biopsy and 24 (59%) had no @entity1 (pathologic CR). Week 14 biopsy during chemoradiation (50 Gy) in 34 (15 previously positive biopsy; 19 no prior biopsy) was negative in 33. Thus 90% of eligible @entity0 completed CRT. Overall survival and EFS were 78% and 55% at 3 years, respectively. Disease progression in 23 @entity0 (37%) was local only in 10 (16%), regional in 5 (8%), local and regional in 2 (3%), and distant in 5 @entity0 (8%). There were no treatment-related @entity3 . @entity2 was primarily hematologic or radiation-related. @entity5 AQUA score was not associated with response/survival. CONCLUSIONS: Induction cetuximab, @entity6 , and @entity7 followed by the same drug CRT is safe and induces high primary site response and promising survival. CLINICAL TRIALS NUMBER: NCT 00089297.

title: Induction cetuximab, @entity6 , and @entity7 followed by chemoradiation with cetuximab, XXXX , and @entity7 for @entity1 : a phase II ECOG-ACRIN trial (E2303).

answer: @entity6


abstract: Dengue is an important and growing public health problem worldwide with an estimated 100million new clinical cases annually. Currently, no licensed drug or vaccine is available. During @entity1 in @entity0 , liver cells constitute one of the main targets of dengue virus (DENV) replication. However, a clear understanding of dengue pathogenesis remains elusive. In order to gain a better reading of the cross talk between virus and host cell proteins, we used a proteomics approach to analyze the host response to DENV infection in a hepatic cell line @entity4 . Differences in proteome expression were assayed 24h post-infection using label-free LC-MS. Quantitative analysis revealed 155 differentially expressed proteins, 64 of which were up-regulated and 91 down-regulated. These results reveal an important decrease in the expression of enzymes involved in the glycolytic pathway, @entity2 cycle, and @entity3 metabolism. This study provides large-scale quantitative information regarding protein expression in the early stages of infection that should be useful for better compression of the pathogenesis of dengue. BIOLOGICAL SIGNIFICANCE: @entity1 involves alterations in the homeostasis of the host cell. Defining the interactions between virus and cell proteins should provide a better understanding of how viruses propagate and cause disease. Here, we present for the first time the proteomic analysis of hepatocytes ( @entity4 cells) infected with DENV-2 by label-free LC-MS. This article is part of a Special Issue entitled: Proteomics, mass spectrometry and peptidomics, Cancun 2013.

title: Quantitative proteomic analysis of XXXX cells infected with Dengue virus by label-free LC-MS.

answer: @entity4


abstract: INTRODUCTION: This study investigated in a community sample associations of 2 different measures of unawareness of @entity6 in @entity4 with @entity1 and behavioral and psychological symptoms of @entity4 . METHOD: Design-cross-sectional, population-based survey. Settings-community samples (n = 15 022) from 3 world regions (Latin America, China, and India). @entity0 -829 @entity0 with @entity4 identified from standardized interviews and diagnostic algorithms. Measurements-unawareness of @entity6 was measured in 2 ways: comparison of @entity0 subjective report with either objective performance on memory tests or informant report (IR). Associations were investigated using prevalence ratios and Poisson regressions. Differences in frequency of unawareness were explored with McNemar tests for each region and agreement between variables calculated with Cohen k. RESULTS: The unawareness variable based on comparison with performance was associated with @entity1 , such as fluency (in China) and @entity1 (Latin America and India), and behavioral symptoms, such as @entity3 (Latin America) and @entity5 (China). The unawareness variable based on IR was associated only with behavioral symptoms, such as @entity2 and @entity3 (Latin America). Frequency of unawareness was significantly higher in the unawareness variable based on performance in India. Agreement between the 2 unawareness variables was moderate in Latin America and China but only slight in India. CONCLUSION: Different ways of measuring unawareness are differentially associated with influencing factors. Informant-based unawareness measures may be more subjective and less sensitive than variables taking into account actual performance on cognitive tests.

title: Neuropsychological and Behavioral Disturbance Correlates of Unawareness of XXXX in @entity4 : A Population-Based Study.

answer: @entity6


abstract: INTRODUCTION: This study investigated in a community sample associations of 2 different measures of unawareness of @entity6 in @entity4 with @entity1 and behavioral and psychological symptoms of @entity4 . METHOD: Design-cross-sectional, population-based survey. Settings-community samples (n = 15 022) from 3 world regions (Latin America, China, and India). @entity0 -829 @entity0 with @entity4 identified from standardized interviews and diagnostic algorithms. Measurements-unawareness of @entity6 was measured in 2 ways: comparison of @entity0 subjective report with either objective performance on memory tests or informant report (IR). Associations were investigated using prevalence ratios and Poisson regressions. Differences in frequency of unawareness were explored with McNemar tests for each region and agreement between variables calculated with Cohen k. RESULTS: The unawareness variable based on comparison with performance was associated with @entity1 , such as fluency (in China) and @entity1 (Latin America and India), and behavioral symptoms, such as @entity3 (Latin America) and @entity5 (China). The unawareness variable based on IR was associated only with behavioral symptoms, such as @entity2 and @entity3 (Latin America). Frequency of unawareness was significantly higher in the unawareness variable based on performance in India. Agreement between the 2 unawareness variables was moderate in Latin America and China but only slight in India. CONCLUSION: Different ways of measuring unawareness are differentially associated with influencing factors. Informant-based unawareness measures may be more subjective and less sensitive than variables taking into account actual performance on cognitive tests.

title: Neuropsychological and Behavioral Disturbance Correlates of Unawareness of @entity6 in XXXX : A Population-Based Study.

answer: @entity4


abstract: OBJECTIVE: We aimed to investigate the bacterial profile and the adequacy of antimicrobial treatment in pregnant @entity0 with @entity1 . MATERIAL AND METHODS: This retrospective observational study was conducted with 753 pregnant @entity0 who needed hospitalization because of UTI in each of the three trimesters. Midstream urine culture and antimicrobial susceptibility tests were evaluated. RESULTS: @entity2 was the most frequently isolated bacterial agent (82.2%), followed by @entity3 @entity4 . (11.2%). In each of the three trimesters, @entity2 remained the most frequently isolated bacterium (86%, 82.2%, 79.5%, respectively), followed by @entity3 @entity4 . (9%, 11.6%, 12.2%, respectively). Enterococcus @entity4 . were isolated as a third microbial agent, with 43 @entity0 (5.7%) in the three trimesters. The bacteria were found to be highly sensitive to @entity6 , with 98-99% sensitivity for @entity2 and 88-89% for @entity3 @entity4 . and for Enterococcus @entity4 . 93-100% @entity5 sensitivity for each of the three trimesters. CONCLUSIONS: We demonstrated that @entity2 and @entity3 @entity4 . are the most common bacterial agents isolated from urine culture of pregnant @entity0 with UTI in each of the three trimesters. We consider @entity6 to be the most adequate first-line treatment regimen due to high sensitivity to the drug, ease of use and safety for use in pregnancy

title: XXXX in pregnant population, which empirical antimicrobial agent should be specified in each of the three trimesters?

answer: @entity1


abstract: OBJECTIVE: To observe the clinicopathological features of pulmonary parenchymal involvement of multicentric @entity8 ( @entity5 ). METHODS: Retrospective analysis was carried out for 6 @entity0 of @entity5 with pulmonary parenchymal involvement who had been admitted to Peking Union Medical College Hospital from July 2008 to March 2013. Relevant literatures were reviewed. The diagnosis was established by surgical lung biopsy and all specimens were fixed in neutral @entity4 and embedded in paraffin. Sections were cut for HE and immunohistochemical stain. B cell and T cell gene rearrangement were tested in 3 cases. RESULTS: These 6 @entity0 (all females) aged 31-68 years, with a median of 49.5 years. The presenting symptoms were @entity2 (4/6), cough (3/6), and @entity6 (6/6). Laboratory study showed elevated ESR (5/6) and CRP (4/6), and hypergammaglobulinaemia (2/6). Chest CT showed multiple nodules with perilymphatic distribution and ground-glass opacity (GGO). Pathologically, there were 5 cases of plasma cell type and 1 case of hyaline vascular type. The plasma cell variant showed dense mature plasma cell infiltration in pulmonary interstitium. The hyaline vascular variant was characterized by the presence of regressed germinal centers and broad concentric mantle zones. The gene arrangement tests were all negative. During the follow-up period (range: 2-60 months; mean: 31 months), 2 cases with plasma cell type received @entity7 chemotherapy and then remained stable. One case with hyaline vascular type received @entity7 chemotherapy but died due to @entity1 . CONCLUSIONS: In the thorax, @entity8 usually manifests as hilar and mediastinal lymph node enlargement. Pulmonary parenchymal involvement by @entity5 is very rare. It is mostly seen in the elderly female, and can manifest with systemic symptoms. Chest CT usually reveals multiple nodules and GGO. It shows similar morphological characteristics to those found in lymph nodes. Immunohistochemistry and gene rearrangement test can help to differentiate it from other @entity3 .

title: [The clinicopathological analysis of pulmonary parenchymal involvement of multicentric @entity8 ( XXXX )].

answer: @entity8


abstract: OBJECTIVE: To observe the clinicopathological features of pulmonary parenchymal involvement of multicentric @entity8 ( @entity5 ). METHODS: Retrospective analysis was carried out for 6 @entity0 of @entity5 with pulmonary parenchymal involvement who had been admitted to Peking Union Medical College Hospital from July 2008 to March 2013. Relevant literatures were reviewed. The diagnosis was established by surgical lung biopsy and all specimens were fixed in neutral @entity4 and embedded in paraffin. Sections were cut for HE and immunohistochemical stain. B cell and T cell gene rearrangement were tested in 3 cases. RESULTS: These 6 @entity0 (all females) aged 31-68 years, with a median of 49.5 years. The presenting symptoms were @entity2 (4/6), cough (3/6), and @entity6 (6/6). Laboratory study showed elevated ESR (5/6) and CRP (4/6), and hypergammaglobulinaemia (2/6). Chest CT showed multiple nodules with perilymphatic distribution and ground-glass opacity (GGO). Pathologically, there were 5 cases of plasma cell type and 1 case of hyaline vascular type. The plasma cell variant showed dense mature plasma cell infiltration in pulmonary interstitium. The hyaline vascular variant was characterized by the presence of regressed germinal centers and broad concentric mantle zones. The gene arrangement tests were all negative. During the follow-up period (range: 2-60 months; mean: 31 months), 2 cases with plasma cell type received @entity7 chemotherapy and then remained stable. One case with hyaline vascular type received @entity7 chemotherapy but died due to @entity1 . CONCLUSIONS: In the thorax, @entity8 usually manifests as hilar and mediastinal lymph node enlargement. Pulmonary parenchymal involvement by @entity5 is very rare. It is mostly seen in the elderly female, and can manifest with systemic symptoms. Chest CT usually reveals multiple nodules and GGO. It shows similar morphological characteristics to those found in lymph nodes. Immunohistochemistry and gene rearrangement test can help to differentiate it from other @entity3 .

title: [The clinicopathological analysis of pulmonary parenchymal involvement of multicentric XXXX ( @entity8 )].

answer: @entity8


abstract: The role of preoperative intrauterine brachytherapy (BT) in the multidisciplinary treatment of @entity1 ( @entity1 ) is controversial. In 2005, a prospective randomized multicenter study was initiated in Hungary in order to explore the potential advantages of preoperative @entity3 ( @entity3 ) BT. In this article we evaluate the efficiency of preoperative @entity3 BT by the rate of pathologic complete remission (pCR) in the first 185 @entity0 enrolled in the study at the National Institute of Oncology and at the Uzsoki Municipal Cancer Center in collaboration with the 1st Department of Gynaecology and Obstetrics of Semmelweis University, Budapest, Hungary. In arm A, @entity0 received 2x8Gy preoperative intracavitary @entity3 BT, while in arm B no preoperative treatment was given. In both arms @entity0 underwent radical Wertheim (Piver III) hysterectomy. The pCR rate was 25.7% after preoperative @entity3 BT, while it was only 11.2% with surgery alone (p=0.03), in these cases the @entity1 was eliminated during the diagnostic excision or conisation. The rate of positive surgical margins was 1.5% after preoperative BT, while it was as high as 11.4% without preoperative @entity2 (p=0.02). There was no significant difference in the @entity1 control (LTC), distant metastases free survival (DMFS) and @entity4 ( @entity4 ) between the two arms. According to our preliminary results preoperative intracavitary @entity3 BT significantly increases the rate of pCR and decreases the rate of positive surgical margins in @entity0 with @entity1 . Longer follow-up is required to establish the possible impact of pCR on the ultimate LTC and @entity4 .

title: Pathologic Complete Remission after Preoperative High-Dose-Rate Brachytherapy in @entity0 with Operable XXXX : Preliminary Results of a Prospective Randomized Multicenter Study.

answer: @entity1


abstract: The role of preoperative intrauterine brachytherapy (BT) in the multidisciplinary treatment of @entity1 ( @entity1 ) is controversial. In 2005, a prospective randomized multicenter study was initiated in Hungary in order to explore the potential advantages of preoperative @entity3 ( @entity3 ) BT. In this article we evaluate the efficiency of preoperative @entity3 BT by the rate of pathologic complete remission (pCR) in the first 185 @entity0 enrolled in the study at the National Institute of Oncology and at the Uzsoki Municipal Cancer Center in collaboration with the 1st Department of Gynaecology and Obstetrics of Semmelweis University, Budapest, Hungary. In arm A, @entity0 received 2x8Gy preoperative intracavitary @entity3 BT, while in arm B no preoperative treatment was given. In both arms @entity0 underwent radical Wertheim (Piver III) hysterectomy. The pCR rate was 25.7% after preoperative @entity3 BT, while it was only 11.2% with surgery alone (p=0.03), in these cases the @entity1 was eliminated during the diagnostic excision or conisation. The rate of positive surgical margins was 1.5% after preoperative BT, while it was as high as 11.4% without preoperative @entity2 (p=0.02). There was no significant difference in the @entity1 control (LTC), distant metastases free survival (DMFS) and @entity4 ( @entity4 ) between the two arms. According to our preliminary results preoperative intracavitary @entity3 BT significantly increases the rate of pCR and decreases the rate of positive surgical margins in @entity0 with @entity1 . Longer follow-up is required to establish the possible impact of pCR on the ultimate LTC and @entity4 .

title: Pathologic Complete Remission after Preoperative High-Dose-Rate Brachytherapy in XXXX with Operable @entity1 : Preliminary Results of a Prospective Randomized Multicenter Study.

answer: @entity0


abstract: PURPOSE: To identify the determinants of short-term and long-term survival in adult @entity0 admitted to intensive care units (ICUs). METHODS: This population-based, observational cohort study included all eleven adult ICUs in the Winnipeg Health Region of Manitoba, Canada, analyzing initial ICU admissions during the period 1999-2010 of all Manitobans >= 17 years old. Analysis included Kaplan-Meier survival curves and multivariable regression models of 30-day mortality and post-90-day survival among those who survived to day 90. We used likelihood ratios to compare the predictive power of clusters of variables in these models. RESULTS: After 33,324 initial ICU admissions, mortality rates within 30 and 90 days were 15.9 and 19.5 %, respectively. The survival curve demonstrated an early phase with a high rate of @entity1 , followed by a markedly lower @entity1 rate that was only clearly established after several months. 30-day mortality was predominantly determined by characteristics of the acute illness; with its relative contribution set at 1.00, the next largest contributors were age (0.19) and comorbidity (0.16). In contrast, post-90-day mortality was mainly determined by age (relative contribution 1.00) and comorbidity (0.95); the next largest contributor was characteristics of acute illness (0.28). CONCLUSIONS: We observed two phases of survival related to @entity2 . Short-term mortality was mainly determined by the acute illness, but its effect decayed relatively rapidly. Mortality beyond 3 months, among those who survived to that point, was mainly determined by age and comorbidity. Recognition of these findings is relevant to discussions with @entity0 and surrogates about achievable goals of care.

title: Distinct determinants of long-term and short-term survival in XXXX .

answer: @entity2


abstract: Cases of congenitally missing and delayed @entity2 of the maxillary first molar are rare. However, in recent years, we have experienced cases of suspected delayed @entity2 of or congenitally missing first molars. The purpose of this study was to analyze the formation of delayed erupted maxillary first molars (M1) (>2 standard deviations), which play important roles in occlusion, and normal @entity2 of the maxillary first molars (U6). The frequency of M1 among @entity0 born between 1974 and 1994 in one institution with a clear total @entity0 number and personal oral histories was 1.55  % [80  % bilateral @entity2 in 8 of 806 male @entity0 (0.99  %) and 23 of 1195 female @entity0 (1.92  %)]. To evaluate the formation and @entity2 of M1 according to Moorrees's tooth formation stages, panoramic X-ray films were obtained every year for 73 @entity0 with M1 from 3 institutions (20 male and 53 female @entity0 , total 131 M1s) without systematic histories or @entity1 . The development/growth curve of M1 was fitted to both the logistic curve and U6 curve. The M1 development/growth curve was started behind with U6 curve; however, the straight part of the M1 curve exhibited steep inclination compared with the straight part of the U6 curve. The curve of the @entity2 pathway of M1 also exhibited a sigmoid S shape. These results indicate that the development and migration speed of M1 are faster than that of U6, excluding the delayed start point. These results may help orthodontists in treatment planning for @entity0 with M1.

title: Formation and development of maxillary first molars with delayed XXXX .

answer: @entity2


abstract: OBJECTIVE: A number of studies showed @entity1 in @entity3 @entity0 but few researches have studied the impact of mood episodes or duration of @entity4 on neuropsychological functioning. METHODS: Cognitive functioning was examined in 110 @entity3 outpatients with different mood state ( @entity3 , @entity5 , mixed episode and euthymia). The neuropsychological battery included The Visual Search Test, @entity6 Making Test, Corsi Test, Frontal Assessment Battery (FAB), Cognitive Estimation Task (CET) and Tower of London and it assessed attention, memory and executive/planning functions. Failures in the different cognitive tests were compared between groups using   (2) tests with Bonferroni's corrections. Finally a binary logistic regression was performed in order to find an eventual association between age and duration of @entity4 and CET bizarreness. RESULTS: All the symptomatic @entity0 ( @entity3 , @entity5 , mixed) failed more frequently The Visual Search Test in comparison with euthymics (  (2)=9.882, df=3, p=0.017, phi=0.30; rate of failures: @entity3 @entity0 32.2%, @entity5 @entity0 30.6%, euthymics 0%, mixed @entity0 18.2%). CET was performed worse by @entity3 and euthymic @entity0 (  (2)=10.086, df=3, p=0.015, phi=0.31; rate of failures: @entity3 @entity0 46.4%, @entity5 @entity0 22.9%, euthymics 52.1%, mixed @entity0 18.2%). Finally, a longer duration of @entity4 was found to be predictive of more bizarreness at CET (OR=1.06, p=0.01). CONCLUSIONS: Bipolar @entity0 present impairment in different cognitive domains even in euthymic phases. @entity2 might be associated with a long duration of @entity4 as shown by number of bizarreness at CET in chronic @entity3 @entity0 .

title: The impact of mood episodes and duration of XXXX on @entity1 .

answer: @entity4


abstract: OBJECTIVE: A number of studies showed @entity1 in @entity3 @entity0 but few researches have studied the impact of mood episodes or duration of @entity4 on neuropsychological functioning. METHODS: Cognitive functioning was examined in 110 @entity3 outpatients with different mood state ( @entity3 , @entity5 , mixed episode and euthymia). The neuropsychological battery included The Visual Search Test, @entity6 Making Test, Corsi Test, Frontal Assessment Battery (FAB), Cognitive Estimation Task (CET) and Tower of London and it assessed attention, memory and executive/planning functions. Failures in the different cognitive tests were compared between groups using   (2) tests with Bonferroni's corrections. Finally a binary logistic regression was performed in order to find an eventual association between age and duration of @entity4 and CET bizarreness. RESULTS: All the symptomatic @entity0 ( @entity3 , @entity5 , mixed) failed more frequently The Visual Search Test in comparison with euthymics (  (2)=9.882, df=3, p=0.017, phi=0.30; rate of failures: @entity3 @entity0 32.2%, @entity5 @entity0 30.6%, euthymics 0%, mixed @entity0 18.2%). CET was performed worse by @entity3 and euthymic @entity0 (  (2)=10.086, df=3, p=0.015, phi=0.31; rate of failures: @entity3 @entity0 46.4%, @entity5 @entity0 22.9%, euthymics 52.1%, mixed @entity0 18.2%). Finally, a longer duration of @entity4 was found to be predictive of more bizarreness at CET (OR=1.06, p=0.01). CONCLUSIONS: Bipolar @entity0 present impairment in different cognitive domains even in euthymic phases. @entity2 might be associated with a long duration of @entity4 as shown by number of bizarreness at CET in chronic @entity3 @entity0 .

title: The impact of mood episodes and duration of @entity4 on XXXX .

answer: @entity1


abstract: @entity4 comprise a constellation of rare clinicopathologic diagnoses characterized by intractable watery diarrhea and @entity1 to thrive in @entity0 . These diagnoses include, but are not limited to, @entity4 ( @entity4 ), @entity3 ( @entity3 ), and enteroendocrine cell dysgenesis (EED). Commonly, the diagnosis is based on identification of their characteristic histologic and/or ultrastructural features in small intestinal mucosa. In cases in which the changes in the small intestine are inconclusive or a small intestine biopsy is not performed, the diagnosis can be hampered or significantly delayed. We describe the histologic features and immunohistochemical staining patterns of @entity2 in @entity0 with confirmed @entity4 (3), @entity3 (2), and EED (1). Specifically, focal epithelial tufts were found in the gastric mucosa of one @entity4 @entity0 and multifocally in the colonic mucosa of another. All @entity4 @entity0 showed complete loss of membranous epithelial @entity5 expression in @entity2 , characteristic of the diagnosis. Gastric biopsies were available in 1 @entity0 with @entity3 ; this showed focal disruption of the gastric glandular architecture. Three colon biopsies and 1 resection from 2 @entity0 with @entity3 showed characteristic cytoplasmic vacuoles and periodic acid-Schiff/villin-positive cytoplasmic inclusions. Chromogranin stains showed complete absence of enteroendocrine cells within the colon and a normal distribution in the gastric mucosa of the EED @entity0 . On the basis of our findings, we conclude that the characteristic histologic and immunohistochemical features associated with the small intestine can be confirmed within the gastric and/or colonic mucosa by careful histologic examination and immunohistochemistry.

title: Features of XXXX in Congenital Enteropathies: A Study in Histology and Immunohistochemistry.

answer: @entity2


abstract: BACKGROUND: @entity3 ( @entity3 ) is an important cause of morbidity and mortality in @entity0 with @entity5 ( @entity5 ). OBJECTIVES: To analyze the outcome and prognostic factors of renal transplantation in @entity0 with @entity3 due to @entity5 from January 1986 to December 2013 in a single center. RESULTS: Fifty renal transplantations were performed in 40 @entity5 @entity0 (32 female (80%), mean age at transplantation 36  10.4 years). The most frequent @entity1 was type IV (72.2%). @entity2 occurred in a total of 15 (30%) transplantations and the causes of graft failure were @entity4 (n=12), acute rejection (n=2), and chronic humoral rejection (1). The death-censored graft survival rates were 93.9% at 1 year, 81.5% at 5 years, and 67.6% at the end of study. The presence of deceased donor allograft (P=0.007) and positive anti-HCV antibodies (P=0.001) negatively influence the survival of the renal transplant. The @entity0 survival rate was 91.4% at the end of the study. Recurrence of @entity6 in renal allograft was observed in one @entity0 . CONCLUSION: Renal transplantation is a good alternative for renal replacement therapy in @entity0 with @entity5 . In our cohort, the presence of anti-HCV antibodies and the type of donor source were related to the development of graft failure.

title: XXXX : outcome and prognostic factors in 50 cases from a single centre.

answer: @entity1


abstract: BACKGROUND: Previous studies have suggested that @entity5 ( @entity5 ) is an independent risk factor for @entity2 . Very few studies have evaluated the relationship between @entity5 and risk of @entity7 ( @entity7 ) requiring dialysis. METHODS: A random sample of 1,000,000 individuals from Taiwan's National Health Insurance database was collected. We selected the control group by matching the subjects and controls by age, @entity1 , @entity3 , @entity4 , @entity6 , area of residence, monthly income and index date. We identified 3985 @entity0 with newly-diagnosed @entity5 between 2000 and 2008 and compared them with a matched cohort of 23910 @entity0 without @entity5 . All @entity0 were tracked from the index date to identify which @entity0 subsequently developed a need for dialysis. RESULTS: The incidence rates of dialysis in the @entity5 cohort and comparison groups were 10.85 and 9.06 per 10000 @entity0 -years, respectively. Stratified by age, the incidence rate ratio for dialysis was greater in @entity5 @entity0 aged <50 years (3.16, 95% CI: 1.62-6.19, p = 0.0008) but not in aged 50-64 (0.94, 95% CI: 0.52-1.69, p = 0.8397) and those aged     65 (0.69, 95% CI: 0.32-1.52, p = 0.3594). After adjustment for @entity0 characteristics and medial comorbidities, the adjusted HR for dialysis remained greater in @entity5 @entity0 aged <50 years (adjusted HR: 2.08, 95% CI: 1.05-4.11, p<0.05). The log-rank test revealed that @entity5 @entity0 <50-years-old had significantly higher cumulative incidence rates of dialysis than those without (p = 0.0004). CONCLUSION: @entity0 with @entity5 , especially younger @entity0 , are at an increased risk for @entity7 requiring dialysis later in life.

title: XXXX and risk of @entity7 requiring dialysis: a nationwide population-based study.

answer: @entity5


abstract: BACKGROUND: Previous studies have suggested that @entity5 ( @entity5 ) is an independent risk factor for @entity2 . Very few studies have evaluated the relationship between @entity5 and risk of @entity7 ( @entity7 ) requiring dialysis. METHODS: A random sample of 1,000,000 individuals from Taiwan's National Health Insurance database was collected. We selected the control group by matching the subjects and controls by age, @entity1 , @entity3 , @entity4 , @entity6 , area of residence, monthly income and index date. We identified 3985 @entity0 with newly-diagnosed @entity5 between 2000 and 2008 and compared them with a matched cohort of 23910 @entity0 without @entity5 . All @entity0 were tracked from the index date to identify which @entity0 subsequently developed a need for dialysis. RESULTS: The incidence rates of dialysis in the @entity5 cohort and comparison groups were 10.85 and 9.06 per 10000 @entity0 -years, respectively. Stratified by age, the incidence rate ratio for dialysis was greater in @entity5 @entity0 aged <50 years (3.16, 95% CI: 1.62-6.19, p = 0.0008) but not in aged 50-64 (0.94, 95% CI: 0.52-1.69, p = 0.8397) and those aged     65 (0.69, 95% CI: 0.32-1.52, p = 0.3594). After adjustment for @entity0 characteristics and medial comorbidities, the adjusted HR for dialysis remained greater in @entity5 @entity0 aged <50 years (adjusted HR: 2.08, 95% CI: 1.05-4.11, p<0.05). The log-rank test revealed that @entity5 @entity0 <50-years-old had significantly higher cumulative incidence rates of dialysis than those without (p = 0.0004). CONCLUSION: @entity0 with @entity5 , especially younger @entity0 , are at an increased risk for @entity7 requiring dialysis later in life.

title: @entity5 and risk of XXXX requiring dialysis: a nationwide population-based study.

answer: @entity7


abstract: BACKGROUND AND STUDY AIMS: @entity4 ( @entity4 ) is an uncommon disease of the tracheobronchial system that leads to narrowing of the airway lumen from @entity3 . The aim of this study is to perform a detailed review of this rare disease in a large cohort of @entity0 with @entity4 proven by fiberoptic bronchoscopy from China. @entity0 AND METHODS: Retrospective chart review was performed on 41,600 @entity0 who underwent bronchoscopy in the Department of Respiratory Medicine of Changhai Hospital between January 2005 and December 2012. Cases of @entity4 were identified based on characteristic features during bronchoscopic examination. RESULTS: 22 cases of bronchoscopic @entity4 were identified. Among whom one-half were male and the mean age was 47.45  10.91 years old. The most frequent symptoms at presentation were chronic cough (n=14) and increased sputum production (n=10). @entity2 were observed in 3/18 @entity0 and findings on computed tomography consistent with @entity4 such as beaded intraluminal calcifications and/or increased luminal thickenings were observed in 18/22 @entity0 . @entity0 were classified into the following categories based on the severity of bronchoscopic findings: Stage I (n=2), Stage II (n=6) and Stage III (n=14). The result that bronchoscopic improvement was observed in 2 @entity0 administered with inhaled corticosteroids suggested that resolution of this disease is possible. CONCLUSIONS: @entity4 is a benign disease with slow progression, which could be roughly divided into 3 stages on the basis of the characteristic endoscopic features and histopathologic findings. @entity1 was thought to be more important than the other existing plausible hypotheses in the course of @entity4 . Inhaled corticosteroids might have some impact on @entity0 at Stage I/II.

title: A clinical study of XXXX osteochondroplastica: findings from a large Chinese cohort.

answer: @entity4


abstract: Spinally administered muscarinic receptor agonists or acetylcholinesterase inhibitors can produce effective @entity2 relief. However, the analgesic mechanisms and the site of actions of cholinergic agents in the spinal cord are not fully understood. In this study, we investigated the mechanisms underlying cholinergic presynaptic regulation of @entity6 release onto spinal dorsal horn neurons. The role of spinal @entity5 (B) receptors in the antinociceptive action of muscarine was also determined. Whole-cell voltage-clamp recordings were performed on visualized dorsal horn neurons in the lamina II in the spinal cord slice preparation of @entity0 . The miniature excitatory postsynaptic currents (mEPSCs) and miniature inhibitory postsynaptic currents (mIPSCs) were recorded in the presence of @entity4 . The evoked EPSCs (eEPSCs) were obtained by electrical stimulation of the dorsal root entry zone or the attached dorsal root. Nociception in @entity0 was measured using a radiant heat stimulus and the effect of intrathecal administration of drugs tested. @entity3 (10-100 microM) reduced the amplitude of monosynaptic eEPSCs in a concentration-dependent manner. @entity3 also significantly decreased the frequency of non- @entity1 receptor-mediated mEPSCs, which was antagonized by @entity7 but not @entity8 . The frequency of @entity5 (A) receptor-mediated mIPSCs was significantly increased by @entity3 and this excitatory effect was abolished by @entity7 . Existence of presynaptic M(2) muscarinic receptors in the spinal dorsal horn was further demonstrated by immunocytochemistry staining and dorsal rhizotomy. @entity9 , a @entity5 (B) receptor antagonist, significantly attenuated the inhibitory effect of @entity3 on the frequency of mEPSCs and the amplitude of monosynaptic eEPSCs in lamina II neurons. Furthermore, the antinociceptive action produced by intrathecal muscarine was significantly reduced by @entity9 pretreatment in @entity0 . Therefore, data from this integrated study provide new information that @entity3 inhibits the glutamatergic synaptic input to lamina II neurons through presynaptic muscarinic receptors. Inhibition of @entity6 release onto lamina II neurons by presynaptic muscarinic and @entity5 (B) heteroreceptors in the spinal cord probably contributes to the antinociceptive action of cholinergic agents.

title: Role of presynaptic muscarinic and @entity5 (B) receptors in spinal XXXX release and cholinergic analgesia in @entity0 .

answer: @entity6


abstract: Spinally administered muscarinic receptor agonists or acetylcholinesterase inhibitors can produce effective @entity2 relief. However, the analgesic mechanisms and the site of actions of cholinergic agents in the spinal cord are not fully understood. In this study, we investigated the mechanisms underlying cholinergic presynaptic regulation of @entity6 release onto spinal dorsal horn neurons. The role of spinal @entity5 (B) receptors in the antinociceptive action of muscarine was also determined. Whole-cell voltage-clamp recordings were performed on visualized dorsal horn neurons in the lamina II in the spinal cord slice preparation of @entity0 . The miniature excitatory postsynaptic currents (mEPSCs) and miniature inhibitory postsynaptic currents (mIPSCs) were recorded in the presence of @entity4 . The evoked EPSCs (eEPSCs) were obtained by electrical stimulation of the dorsal root entry zone or the attached dorsal root. Nociception in @entity0 was measured using a radiant heat stimulus and the effect of intrathecal administration of drugs tested. @entity3 (10-100 microM) reduced the amplitude of monosynaptic eEPSCs in a concentration-dependent manner. @entity3 also significantly decreased the frequency of non- @entity1 receptor-mediated mEPSCs, which was antagonized by @entity7 but not @entity8 . The frequency of @entity5 (A) receptor-mediated mIPSCs was significantly increased by @entity3 and this excitatory effect was abolished by @entity7 . Existence of presynaptic M(2) muscarinic receptors in the spinal dorsal horn was further demonstrated by immunocytochemistry staining and dorsal rhizotomy. @entity9 , a @entity5 (B) receptor antagonist, significantly attenuated the inhibitory effect of @entity3 on the frequency of mEPSCs and the amplitude of monosynaptic eEPSCs in lamina II neurons. Furthermore, the antinociceptive action produced by intrathecal muscarine was significantly reduced by @entity9 pretreatment in @entity0 . Therefore, data from this integrated study provide new information that @entity3 inhibits the glutamatergic synaptic input to lamina II neurons through presynaptic muscarinic receptors. Inhibition of @entity6 release onto lamina II neurons by presynaptic muscarinic and @entity5 (B) heteroreceptors in the spinal cord probably contributes to the antinociceptive action of cholinergic agents.

title: Role of presynaptic muscarinic and XXXX (B) receptors in spinal @entity6 release and cholinergic analgesia in @entity0 .

answer: @entity5


abstract: Spinally administered muscarinic receptor agonists or acetylcholinesterase inhibitors can produce effective @entity2 relief. However, the analgesic mechanisms and the site of actions of cholinergic agents in the spinal cord are not fully understood. In this study, we investigated the mechanisms underlying cholinergic presynaptic regulation of @entity6 release onto spinal dorsal horn neurons. The role of spinal @entity5 (B) receptors in the antinociceptive action of muscarine was also determined. Whole-cell voltage-clamp recordings were performed on visualized dorsal horn neurons in the lamina II in the spinal cord slice preparation of @entity0 . The miniature excitatory postsynaptic currents (mEPSCs) and miniature inhibitory postsynaptic currents (mIPSCs) were recorded in the presence of @entity4 . The evoked EPSCs (eEPSCs) were obtained by electrical stimulation of the dorsal root entry zone or the attached dorsal root. Nociception in @entity0 was measured using a radiant heat stimulus and the effect of intrathecal administration of drugs tested. @entity3 (10-100 microM) reduced the amplitude of monosynaptic eEPSCs in a concentration-dependent manner. @entity3 also significantly decreased the frequency of non- @entity1 receptor-mediated mEPSCs, which was antagonized by @entity7 but not @entity8 . The frequency of @entity5 (A) receptor-mediated mIPSCs was significantly increased by @entity3 and this excitatory effect was abolished by @entity7 . Existence of presynaptic M(2) muscarinic receptors in the spinal dorsal horn was further demonstrated by immunocytochemistry staining and dorsal rhizotomy. @entity9 , a @entity5 (B) receptor antagonist, significantly attenuated the inhibitory effect of @entity3 on the frequency of mEPSCs and the amplitude of monosynaptic eEPSCs in lamina II neurons. Furthermore, the antinociceptive action produced by intrathecal muscarine was significantly reduced by @entity9 pretreatment in @entity0 . Therefore, data from this integrated study provide new information that @entity3 inhibits the glutamatergic synaptic input to lamina II neurons through presynaptic muscarinic receptors. Inhibition of @entity6 release onto lamina II neurons by presynaptic muscarinic and @entity5 (B) heteroreceptors in the spinal cord probably contributes to the antinociceptive action of cholinergic agents.

title: Role of presynaptic muscarinic and @entity5 (B) receptors in spinal @entity6 release and cholinergic analgesia in XXXX .

answer: @entity0


abstract: Cell walls prepared from the endosperm tissue of hydrated lettuce ( @entity7 .) seeds undergo autohydrolysis. Release of @entity2 is most rapid (0.4-0.6 [mu]g per endosperm) within the 1st h of incubation in buffer, but substantial autolysis is sustained for at least 10 h. Autolysis is temperature sensitive, and the optimum rate occurs at pH 5. The rate of autolysis increases markedly in the period just prior to radicle emergence. The cell-wall polysaccharide composition in micropylar and lateral endosperm regions differs significantly; the micropylar walls are rich in @entity5 and @entity0 with substantially lower amounts of @entity4 . Although walls prepared from both micropylar and lateral regions undergo autolysis, micropylar walls release @entity2 at a higher rate than lateral walls. Autolysis products elute as large polymers when subjected to size-exclusion chromatography, suggesting that endo-enzyme activity is responsible for release of fragments containing @entity5 , @entity3 , @entity4 , and uronic acids. @entity5 , @entity3 , @entity4 , and @entity0 are also released as monomers. As a function of time, the ratio of polymers to monomers decreases, indicating that exo-enzyme activity is also present. Thermoinhibition or treatment with @entity1 suppresses germination and reduces the rates of autolysis of walls isolated from the endosperm by about 25%. Treatments that alleviate thermoinhibition (kinetin and @entity6 ) increase the rates of autolysis by 20 to 30% when compared to thermoinhibited controls.

title: Cell-Wall Autohydrolysis in Isolated Endosperms of Lettuce ( XXXX .).

answer: @entity7


abstract: We investigated mechanisms involved in inhibition of @entity4 ( @entity4 .) leaf-elongation growth following addition of non-penetrating osmolyte to the root medium. The elongation rate of the first true leaf remained inhibited for 4 h after addition of @entity0 ( @entity1 ; -0.5 MPa water potential), despite progressive osmotic adjustment in the growing leaf tissues. Thus, inhibition of leaf growth did not appear to be directly related to loss of leaf capacity to maintain osmotic potential gradients. Comparative cell-wall-extension capacities of immature (still expanding) leaf tissues were measured by creep extensiometry using whole plants. Reductions in irreversible (plastic) extension capacity (i.e. wall hardening) were detected minutes and hours after addition of @entity1 to the roots, by both in vivo and in vitro assay. The onset of the wall-hardening response could be detected by in vitro assay only 2 min after addition of @entity1 . Thus, initiation of wall hardening appeared to precede transcription-regulated responses. The inhibition of both leaf growth and wall-extension capacity was reversed by removal of @entity1 after 4 h. Moreover, wall hardening could be induced by other osmolytes ( @entity3 , @entity2 ). Thus, the leaf responses did not appear to be related to any specific (toxic) effect of @entity1 . We conclude that hardening of leaf cell walls is a primary event in the chain of growth regulatory responses to @entity1 -induced water deficits in @entity4 . The signaling processes by which @entity1 , which is not expected to penetrate root cell walls or membranes, might cause cell-wall hardening in relatively distant leaves was also investigated. Plants with live or killed roots were exposed to @entity1 . The killed roots were presumed to be unable to produce hormonal or electrical signals in response to addition of @entity1 ; however, inhibition of leaf elongation and hardening of leaf cell walls were detected with both live and killed roots. Thus, neither hormonal signaling nor signaling via induced changes in surface electrical potential were necessary, and hydraulic signals appeared to generate the leaf responses.

title: Hydraulic Signals from the Roots and Rapid Cell-Wall Hardening in Growing XXXX ( @entity4 .) Leaves Are Primary Responses to @entity0 -Induced Water Deficits.

answer: @entity4


abstract: We investigated mechanisms involved in inhibition of @entity4 ( @entity4 .) leaf-elongation growth following addition of non-penetrating osmolyte to the root medium. The elongation rate of the first true leaf remained inhibited for 4 h after addition of @entity0 ( @entity1 ; -0.5 MPa water potential), despite progressive osmotic adjustment in the growing leaf tissues. Thus, inhibition of leaf growth did not appear to be directly related to loss of leaf capacity to maintain osmotic potential gradients. Comparative cell-wall-extension capacities of immature (still expanding) leaf tissues were measured by creep extensiometry using whole plants. Reductions in irreversible (plastic) extension capacity (i.e. wall hardening) were detected minutes and hours after addition of @entity1 to the roots, by both in vivo and in vitro assay. The onset of the wall-hardening response could be detected by in vitro assay only 2 min after addition of @entity1 . Thus, initiation of wall hardening appeared to precede transcription-regulated responses. The inhibition of both leaf growth and wall-extension capacity was reversed by removal of @entity1 after 4 h. Moreover, wall hardening could be induced by other osmolytes ( @entity3 , @entity2 ). Thus, the leaf responses did not appear to be related to any specific (toxic) effect of @entity1 . We conclude that hardening of leaf cell walls is a primary event in the chain of growth regulatory responses to @entity1 -induced water deficits in @entity4 . The signaling processes by which @entity1 , which is not expected to penetrate root cell walls or membranes, might cause cell-wall hardening in relatively distant leaves was also investigated. Plants with live or killed roots were exposed to @entity1 . The killed roots were presumed to be unable to produce hormonal or electrical signals in response to addition of @entity1 ; however, inhibition of leaf elongation and hardening of leaf cell walls were detected with both live and killed roots. Thus, neither hormonal signaling nor signaling via induced changes in surface electrical potential were necessary, and hydraulic signals appeared to generate the leaf responses.

title: Hydraulic Signals from the Roots and Rapid Cell-Wall Hardening in Growing @entity4 ( XXXX .) Leaves Are Primary Responses to @entity0 -Induced Water Deficits.

answer: @entity4


abstract: We investigated mechanisms involved in inhibition of @entity4 ( @entity4 .) leaf-elongation growth following addition of non-penetrating osmolyte to the root medium. The elongation rate of the first true leaf remained inhibited for 4 h after addition of @entity0 ( @entity1 ; -0.5 MPa water potential), despite progressive osmotic adjustment in the growing leaf tissues. Thus, inhibition of leaf growth did not appear to be directly related to loss of leaf capacity to maintain osmotic potential gradients. Comparative cell-wall-extension capacities of immature (still expanding) leaf tissues were measured by creep extensiometry using whole plants. Reductions in irreversible (plastic) extension capacity (i.e. wall hardening) were detected minutes and hours after addition of @entity1 to the roots, by both in vivo and in vitro assay. The onset of the wall-hardening response could be detected by in vitro assay only 2 min after addition of @entity1 . Thus, initiation of wall hardening appeared to precede transcription-regulated responses. The inhibition of both leaf growth and wall-extension capacity was reversed by removal of @entity1 after 4 h. Moreover, wall hardening could be induced by other osmolytes ( @entity3 , @entity2 ). Thus, the leaf responses did not appear to be related to any specific (toxic) effect of @entity1 . We conclude that hardening of leaf cell walls is a primary event in the chain of growth regulatory responses to @entity1 -induced water deficits in @entity4 . The signaling processes by which @entity1 , which is not expected to penetrate root cell walls or membranes, might cause cell-wall hardening in relatively distant leaves was also investigated. Plants with live or killed roots were exposed to @entity1 . The killed roots were presumed to be unable to produce hormonal or electrical signals in response to addition of @entity1 ; however, inhibition of leaf elongation and hardening of leaf cell walls were detected with both live and killed roots. Thus, neither hormonal signaling nor signaling via induced changes in surface electrical potential were necessary, and hydraulic signals appeared to generate the leaf responses.

title: Hydraulic Signals from the Roots and Rapid Cell-Wall Hardening in Growing @entity4 ( @entity4 .) Leaves Are Primary Responses to XXXX -Induced Water Deficits.

answer: @entity0


abstract: Early quality of life benefits of icodextrin in @entity2 . BACKGROUND: The impact of new therapies on @entity0 quality of life (QOL) is emerging as an important indicator of the value of these therapies. In @entity0 on dialysis, previous QOL evaluations have focused mainly on comparative approaches between modalities, or on longitudinal trends within a modality, but few have evaluated technical innovations or introduction of new therapies. The aim of the present study was to assess the early effects of a new dialysis solution (icodextrin) on the QOL of @entity2 @entity0 . The QOL is compared with that of @entity0 on @entity3 , and the impact of demographic, and clinical characteristics on @entity0 ' QOL is examined. METHODS: The @entity1 quality of life questionnaire (KDQOL) was administered to @entity0 who participated in a phase III double-blind, parallel group, active-controlled trial to evaluate the efficacy and safety of a @entity2 ( @entity2 ) solution containing icodextrin in comparison with @entity3 @entity2 solution. A total of 93 @entity0 (58 icodextrin, and 35 @entity3 ) completed the questionnaire at both baseline and after 13 weeks. In addition to @entity0 QOL, @entity0 ' demographic and clinical characteristics were recorded at both baseline and 13 weeks. RESULTS: Mean change scores from baseline to 13 weeks of icodextrin @entity0 were substantially higher (> or =5) than @entity3 , particularly with respect to general health perception, physical functioning, role-physical, and many KDQOL symptom items such as lack of strength, washed out or drained, lack of appetite, @entity4 or @entity5 , dry skin, cramps after an exchange or treatment, cramps during an exchange or treatment, and @entity6 or twitching. At 13 weeks, icodextrin @entity0 had significantly improved symptoms, and rated their health in general higher than those @entity0 in the @entity3 group. Upon multivariate analysis, icodextrin contributed significantly to the improvement of @entity0 ' mental health, general health, and symptoms such as @entity6 or twitching, cramps during an exchange or treatment, cramps after an exchange or treatment, itchy skin, and @entity4 or @entity5 . CONCLUSIONS: Peritoneal dialysis @entity0 treated with icodextrin experienced substantial quality of life improvement at 13 weeks after the start of treatment when compared to @entity3 @entity0 . Further research is necessary to determine @entity0 ' quality of life over time in a longitudinal study setting.

title: Early quality of life benefits of icodextrin in XXXX .

answer: @entity2


abstract: BACKGROUND: Reconstruction of the head and neck after adequate resection of @entity1 and neck dissection is a challenge. It should be performed at one sitting in advanced @entity1 . Defects caused by the resection should be closed with flaps which match in color, texture and hair bearing characteristics with the face. Cervicopectoral flap is a one such flap from chest and neck skin mainly used to cover the cheek defects. METHODS: This study included twelve @entity0 presenting with @entity2 to Izmir Ataturk Training Hospital and Adnan Menderes University Hospital. @entity1 resection and neck dissection was performed in one session by the same surgeon. A single incision was made and a medially based cervicopectoral fascio-cutaneous flap was used for surgical exposure in neck dissection and for closure of defects after @entity1 resection. RESULTS: There was no major complication. Two flaps had partial superficial epidermolysis at the suture line. Good aesthetic and functional results were achieved. CONCLUSION: The cervicopectoral flap is an excellent alternative for the reconstruction of head and neck. Harvesting and application of the flap is rapid and safe. Only a single incision is sufficient for dissection and flap elevation. This flap achieves perfect surgical exposure, makes neck dissection easy and allows one to perform both @entity1 resection and neck dissection in one session.

title: Cervicopectoral flap in XXXX surgery.

answer: @entity2


abstract: OBJECTIVE: To evaluate the efficacy and safety of domestic @entity1 in the treatment of @entity0 with stage IIIB approximately IV @entity6 ( @entity6 ). METHODS: 124 @entity6 @entity0 were randomized into three groups: Group A: single drug group, 40 cases, @entity1 1 000 mg/m(2) + NS 100 ml or 200 ml was infused within 30 approximately 60 minutes on D1, 8 and 15, with 28 days taken as one cycle. Group B: combined treatment group, 36 cases, in addition to the above protocol, @entity5 30 mg/m(2) was infused within 60 approximately 120 min, on @entity9 . Group C: combined control group: 39 cases, the protocol applied was the same as group B except domestic @entity1 being replaced by imported gemzar. The efficacy and side effects of treatment were evaluated after 8 weeks of treatment. RESULTS: 115 @entity0 could be evaluated for response rate. PR was observed in 9/40 (22.5%) of group A, 15/36 (41.6%) in group B and 15/39 (38.36%) in group C. There was no significant difference of PR rates between group B and group C (P = 0.552). 117 @entity0 who received the second cycle of treatment were evaluated for @entity2 . The incidence of grade III approximately IV @entity3 , @entity4 and @entity7 was much higher in group B. @entity8 of groups B and C was higher than that of group A. There was no significant difference between groups B and C. CONCLUSION: The efficacy and incidence of side effects between domestic @entity1 and the imported gemzar are similar.

title: [Phase II clinical trial on @entity1 in the treatment of stage IIIB-IV XXXX ].

answer: @entity6


abstract: OBJECTIVE: To evaluate the efficacy and safety of domestic @entity1 in the treatment of @entity0 with stage IIIB approximately IV @entity6 ( @entity6 ). METHODS: 124 @entity6 @entity0 were randomized into three groups: Group A: single drug group, 40 cases, @entity1 1 000 mg/m(2) + NS 100 ml or 200 ml was infused within 30 approximately 60 minutes on D1, 8 and 15, with 28 days taken as one cycle. Group B: combined treatment group, 36 cases, in addition to the above protocol, @entity5 30 mg/m(2) was infused within 60 approximately 120 min, on @entity9 . Group C: combined control group: 39 cases, the protocol applied was the same as group B except domestic @entity1 being replaced by imported gemzar. The efficacy and side effects of treatment were evaluated after 8 weeks of treatment. RESULTS: 115 @entity0 could be evaluated for response rate. PR was observed in 9/40 (22.5%) of group A, 15/36 (41.6%) in group B and 15/39 (38.36%) in group C. There was no significant difference of PR rates between group B and group C (P = 0.552). 117 @entity0 who received the second cycle of treatment were evaluated for @entity2 . The incidence of grade III approximately IV @entity3 , @entity4 and @entity7 was much higher in group B. @entity8 of groups B and C was higher than that of group A. There was no significant difference between groups B and C. CONCLUSION: The efficacy and incidence of side effects between domestic @entity1 and the imported gemzar are similar.

title: [Phase II clinical trial on XXXX in the treatment of stage IIIB-IV @entity6 ].

answer: @entity1


abstract: OBJECTIVE: To determine the clinical and microbiologic characteristics of @entity3 at Sanatorio Mitre, Buenos Aires, Argentina. METHODS: One-hundred-and-seven episodes of @entity3 were prospectively analyzed from 1993 to 1998. Demographics, clinical and microbiological variables were studied. RESULTS: Eighty-one @entity0 (76%) were adults and 26 @entity0 (24%). Most cases (98%) were acquired in the community. Seventy-nine @entity0 (74%) had at least one underlying condition. The primary source of @entity3 was found in 91 @entity0 (85%), the lungs being the most common source. @entity2 was isolated from one sterile site other than the primary focus in 25 @entity0 (23%). Eighty-five (79%) of the @entity2 were susceptible to @entity1 and 22 (21%) showed intermediate or high resistance to @entity1 and 2% were additionally resistant to @entity4 . Initial antimicrobial therapy was appropriate in 95% of the cases. The overall mortality was 21%, however adults admitted to the intensive care unit (ICU) had higher mortality (81%). No @entity0 under 14 years old died. Multivariate analysis showed that age and recovery of the organisms from a sterile site other than the primary focus were statistically significant predictors of mortality. CONCLUSION: @entity5 continue to be an important worldwide problem causing morbidity and high mortality despite supportive care and appropriate antimicrobial therapy.

title: XXXX in a single center in Argentina.

answer: @entity3


abstract: AIMS: We investigated changes in the distribution of @entity1 consumption by education and marital status in Russia during the period of societal transformation after 1990. Such changes would indicate the potential role of @entity1 in the rising social inequalities in mortality. METHODS: We analysed data from three surveys in random population samples conducted in Novosibirsk as part of the WHO MONICA project in 1985/86 (1533 @entity0 , 1292 @entity0 ), 1988/89 (1700 @entity0 , no @entity0 ) and 1994/95 (1526 @entity0 , 1510 @entity0 ), coinciding with the period of societal transformation. Four measures of drinking were examined in relation to education and marital status: prevalence of drinking at least twice a week; the mean intake in the last week; the mean intake per drinking occasion; and the prevalence of binge drinking (>80 g @entity2 for @entity0 and >60 g for @entity0 ) at least once a month. RESULTS: Among @entity0 , those with university education had the lowest levels of all measures of drinking. Drinking indices increased over time in all educational groups but most sharply in @entity0 with high education, thus leading to a smaller education-related difference in the last survey. With respect to marital status, divorced and widowed @entity0 tended to drink most, but the pattern was inconsistent, and the difference between divorced and married @entity0 also narrowed over time. Among @entity0 , @entity1 intake increased between the first and last survey. Differences by education and marital status in @entity0 were smaller than in @entity0 , and binge drinking was inversely related to education. CONCLUSIONS: All indices of @entity1 consumption in @entity0 increased between the mid 1980s and the mid 1990s. The increase in @entity1 intake among @entity0 was proportionally similar across categories of education and marital status but the absolute differences increased. The contribution of @entity1 to the increase in social differentials in mortality in the 1990s was probably modest.

title: Trends in XXXX intake by education and marital status in urban population in Russia between the mid 1980s and the mid 1990s.

answer: @entity1


abstract: A case of a 50-year-old, right-handed female, mono-lingual native Spanish-speaker with a university-level education and cognitive changes is reported. Over approximately 2 years, she presented with a progressive deterioration of writing abilities associated with @entity7 and @entity9 . An MRI disclosed a left parietal temporal @entity2 . Two years later, further significant @entity1 consistent with a @entity4 of the @entity3 was observed. @entity8 , @entity5 , and @entity10 were found. Writing was severely impaired, and some difficulties in reading were observed. Copying abilities, however, were relatively well preserved, and the @entity0 could drive and go to different city locations without significant spatial orientation difficulties. A second MRI approximately 2 years later showed that @entity6 had progressed significantly. Spontaneous writing and writing to dictation were impossible. The ability to read words was preserved, but the ability to read pseudowords was lost. Changes in calligraphy were noted. This case clearly illustrates the progression of focal @entity1 over time and the spread of abnormalities to other domains.

title: Progressive agraphia, @entity7 , and XXXX : a single case report.

answer: @entity9


abstract: A case of a 50-year-old, right-handed female, mono-lingual native Spanish-speaker with a university-level education and cognitive changes is reported. Over approximately 2 years, she presented with a progressive deterioration of writing abilities associated with @entity7 and @entity9 . An MRI disclosed a left parietal temporal @entity2 . Two years later, further significant @entity1 consistent with a @entity4 of the @entity3 was observed. @entity8 , @entity5 , and @entity10 were found. Writing was severely impaired, and some difficulties in reading were observed. Copying abilities, however, were relatively well preserved, and the @entity0 could drive and go to different city locations without significant spatial orientation difficulties. A second MRI approximately 2 years later showed that @entity6 had progressed significantly. Spontaneous writing and writing to dictation were impossible. The ability to read words was preserved, but the ability to read pseudowords was lost. Changes in calligraphy were noted. This case clearly illustrates the progression of focal @entity1 over time and the spread of abnormalities to other domains.

title: Progressive agraphia, XXXX , and @entity9 : a single case report.

answer: @entity7


abstract: Our preliminary observations on a small group of @entity4 ( @entity4 ) @entity0 indicated a change in the non-nociceptive, tactile sensory function in @entity4 and provided evidence for the hypothesis of a neuropathic etiology of @entity4 . In the present clinical study on a group of 52 @entity4 @entity0 , we used quantitative sensory tests (QST) in addition to the blink reflex (BR) recordings in order to gain further insight into the neural mechanisms of @entity1 . Based on electrophysiologic findings, the @entity4 @entity0 could be grouped into four different categories: (1) The results of the BR were suggestive of brainstem pathology or peripheral trigeminal neuropathy in ten (19%) @entity0 . In most of the cases, the abnormalities in the BR seemed to represent subclinical changes of the trigeminal system. (2) Increased excitability of the BR was found in the form of deficient habituation of the R2 component of the BR in 11 (21%) of the @entity0 . Two of these @entity0 also showed signs of warm @entity3 in QST. (3) One or more of the sensory thresholds were abnormal indicating thin fiber dysfunction in altogether 35 @entity0 (76%) out of the 46 tested with QST. Thirty-three of these @entity0 showed signs of @entity2 . (4) There were only five @entity0 with normal findings in both tests. The present findings with strong evidence for neuropathic background in @entity4 will hopefully provide insights for new therapeutic strategies.

title: Sensory dysfunction in XXXX .

answer: @entity4


abstract: Our data suggest that lymph-node size is not a reliable indicator for lymph-node @entity1 in gastric, esophageal, and @entity5 . Despite a significant difference in diameter of metastatic and non-metastatic nodes, the accurate evaluation of lymph-node @entity1 in @entity6 cannot be determined by nodal size, because the majority of counted lymph nodes is ?5 mm and the frequency of small lymph-node @entity1 is high. Therefore imaging techniques using the size as criterion of nodal infiltration can not exactly assess the nodal status of @entity0 with @entity6 . For rational lymphadenectomy, the value of sentinel node biopsy in @entity2 is now discussed. At the moment it is too early to apply sentinel node biopsy in order to reduce the extent of lymphadenectomy in these @entity3 [11]. Recent interest has focused on PET scanning in the detection of lymph-node @entity1 . PET represents a potentially ideal imaging modality for @entity2 . It allows a quick and simultaneous assessment of both local and distant sites and, as a result of avid uptake of the @entity4 moiety, may potentially identify small @entity2 loads. There are only limited experience in detecting lymph-node @entity1 in @entity6 and the results of the published reports are controversially discussed [12, 13]. Our data demonstrate a high frequency of small lymph-node @entity1 in @entity6 and suggest that a careful histological search for small lymph-node @entity1 should be undertaken to avoid false-negative lymph-node staging. These results emphasize that a reliable pathological @entity2 must be based on a standardized systematic lymphadenectomy because lymph-node sampling based on lymph-node size is not sufficient.

title: Preoperative lymph-node staging in gastrointestinal cancer--correlation between size and XXXX stage.

answer: @entity2


abstract: PURPOSE: To determine the influence of two different pretreatment intervals, i.e. 3 and 6 min, on the efficacy of 0.01 mg/kg @entity5 in preventing @entity6 -induced @entity7 and @entity3 . METHODS: A total of 60 adult @entity0 were randomized and received either 0.01 mg/kg @entity5 (0.2*ED(95)) i.v. ( @entity8 group: pretreatment interval 3 min, @entity9 group: pretreatment interval 6 min) or normal saline i.v. (placebo group) prior to injection of @entity6 . The incidence and severity of @entity7 and @entity3 and side-effects of precurarization were assessed. RESULTS: The incidence of @entity7 was only reduced in the @entity9 group (45%) compared with the Placebo group (85%), p<0.05. @entity5 was associated with a higher incidence of @entity4 in both pretreatment groups ( @entity8 : 75%, @entity9 : 80%) compared with the Placebo group (30%), p<0.05. CONCLUSION: @entity5 is only effective in preventing @entity6 -induced @entity7 when a longer pretreatment interval, i.e. 6 min instead of 3 min, is chosen. Precurarization led to signs of @entity2 in both pretreatment groups in the majority (75-80%) of @entity0 without reducing the incidence or severity of @entity1 .

title: [Precurarization of XXXX with @entity5 : the influence of the precurarization interval].

answer: @entity6


abstract: PURPOSE: To determine the influence of two different pretreatment intervals, i.e. 3 and 6 min, on the efficacy of 0.01 mg/kg @entity5 in preventing @entity6 -induced @entity7 and @entity3 . METHODS: A total of 60 adult @entity0 were randomized and received either 0.01 mg/kg @entity5 (0.2*ED(95)) i.v. ( @entity8 group: pretreatment interval 3 min, @entity9 group: pretreatment interval 6 min) or normal saline i.v. (placebo group) prior to injection of @entity6 . The incidence and severity of @entity7 and @entity3 and side-effects of precurarization were assessed. RESULTS: The incidence of @entity7 was only reduced in the @entity9 group (45%) compared with the Placebo group (85%), p<0.05. @entity5 was associated with a higher incidence of @entity4 in both pretreatment groups ( @entity8 : 75%, @entity9 : 80%) compared with the Placebo group (30%), p<0.05. CONCLUSION: @entity5 is only effective in preventing @entity6 -induced @entity7 when a longer pretreatment interval, i.e. 6 min instead of 3 min, is chosen. Precurarization led to signs of @entity2 in both pretreatment groups in the majority (75-80%) of @entity0 without reducing the incidence or severity of @entity1 .

title: [Precurarization of @entity6 with XXXX : the influence of the precurarization interval].

answer: @entity5


abstract: Because quantitative ultrasound (QUS) instruments from different manufacturers have significant technical differences, it is difficult to assess whether all of them can discriminate similarly between @entity3 and age-matched controls. Thus, to avoid any bias, reliable comparative assessment of the QUS devices should be carried out on the same population. Few studies have fulfilled this condition. Another source of variability in cross-sectional studies in which @entity2 and nonfractured subjects are compared is the time since @entity3 . Our study evaluated the ability of three calcaneal QUS devices to discriminate @entity0 with @entity1 from control subjects, using the same population. In addition, a subset of @entity0 was re-measured about 9 months after the hip replacement surgery to check how the time since @entity2 affects the discriminatory ability of the different QUS devices. Fifty postmenopausal @entity1 @entity0 and 46 postmenopausal age-matched controls were included in this study and measured on three QUS devices, as well as 50 young healthy controls to calculate the T-score. Odds ratio results showed that a decrease in UBIS trade mark BUA of 1 SD was associated with a significant increase in @entity2 risk (odds ratio adjusted = 2.30) comparable with Sahara broadband ultrasound attenuation (BUA) (OR adj. = 2.30), and Achilles BUA (OR adj. = 3.5). However, given the large overlap between the 95% intervals of each OR and for the areas under ROC curves, no significant difference was found between them. In the subset of 15 @entity1 subjects, no significant differences were found between ultrasound parameters of the first visit and 9 months after except for the heel width (soft tissue variation). Odds ratio and areas under the curve (AUC) tend to increase from visit 1 to 2 for the BUA and decrease substantially for the SOS for all but the Lunar Achilles+. Nonsignificant correlation was found between the absolute difference of the ultrasound parameters measured at the two visits and the time since @entity2 , except for the Sahara SOS (r = 0.45; P < 0.04). In conclusion, no significant differences between QUS technologies were observed in their positive and significant ability to discriminate @entity1 @entity0 from controls. However, this statement is shadowed when taking into account the time since @entity2 which seems to negatively influence results obtained on dry versus wet QUS systems. As a result, it is advisable that such parameters would be taken into account when designing a study aimed to demonstrate the discriminatory ability of heel ultrasound between normal and @entity1 @entity0 .

title: Is time since @entity1 influencing the discrimination between XXXX and nonfractured subjects as assessed at the calcaneum by three technologically different quantitative ultrasound devices?

answer: @entity2